Author: Hu, Xingsheng; Hu, Chunhong; Jiang, Dixuan; Zuo, Qian; Li, Ya; Wang, Yang; Chen, Xiangyu
Title: Effectiveness of Convalescent Plasma Therapy for COVID-19 Patients in Hunan, China Cord-id: gpk846e3 Document date: 2020_12_15
ID: gpk846e3
Snippet: OBJECTIVE: To investigate clinical efficacy and safety of convalescent plasma (CP) therapy in coronavirus disease 2019 (COVID-19) patients. METHODS: We included 4 severe patients and 3 critical patients. The date of admission to hospital ranged from January 30 to February 19, 2020. We retrospectively collected clinical and outcome data. Relative parameters were compared. RESULTS: After CP therapy, the symptoms and respiratory functions were improved. Median PaO(2)/FIO(2) increased from 254 (142-
Document: OBJECTIVE: To investigate clinical efficacy and safety of convalescent plasma (CP) therapy in coronavirus disease 2019 (COVID-19) patients. METHODS: We included 4 severe patients and 3 critical patients. The date of admission to hospital ranged from January 30 to February 19, 2020. We retrospectively collected clinical and outcome data. Relative parameters were compared. RESULTS: After CP therapy, the symptoms and respiratory functions were improved. Median PaO(2)/FIO(2) increased from 254 (142-331) to 326 (163–364), and dependence of oxygen supply decreased. Median time to lesion’s first absorption was 5 (2–7) days, undetectable viral RNA was 11 (3.5–15.7) days. Median lymphocyte count (0.77 × 10(9)/L vs 0.85 × 10(9)/L) and albumin level (31g/L vs 36 g/L) were elevated, C-reactive protein (44 mg/L vs 18 mg/L), D-dimer (5.9 mg/L vs 4 mg/L) and lactate dehydrogenase (263 U/L vs 245 U/L) decreased. No obvious adverse reactions were observed. At the follow-up on June 14, 2020, 6 patients had completely recovered and one died from terminal disease. CONCLUSION: CP therapy for COVID-19 was effective and safe. Three patients who did not combine with antiviral therapy after CP also obtained viral clearance and clinical improvement. However, CP therapy failed to save the life of a terminally ill patient.
Search related documents:
Co phrase search for related documents- acid level and acute kidney injury: 1
- acid level and acute lung injury: 1, 2
- acid level and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
- acid level and lopinavir ritonavir: 1
- acid level and low mortality rate: 1, 2
- acid level and low white cell count: 1
- acid level and lung injury: 1, 2
- acid level and lymphocyte count: 1
- acute ards respiratory distress syndrome and address need: 1, 2, 3, 4, 5, 6, 7
- acute ards respiratory distress syndrome and local area: 1
- acute ards respiratory distress syndrome and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35
- acute ards respiratory distress syndrome and low lymphocyte count: 1, 2
- acute ards respiratory distress syndrome and low mortality rate: 1, 2, 3, 4
- acute ards respiratory distress syndrome and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75
- acute ards respiratory distress syndrome and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37
- acute kidney injury and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
- acute kidney injury and low lymphocyte count: 1
- acute kidney injury and low mortality rate: 1
- acute kidney injury and low white cell count: 1
Co phrase search for related documents, hyperlinks ordered by date